Cargando…

Tumour necrosis factor inhibitor tapering in patients with ankylosing spondylitis at low disease activity: factors associated with flare

BACKGROUND: To investigate factors associated with flare in patients with ankylosing spondylitis (AS) who tapered tumour necrosis factor inhibitors (TNFis) after achievement of low disease activity (LDA) with the standard dose of TNFis. METHODS: This retrospective cohort study included 101 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwon, Oh Chan, Park, Jung Hwan, Park, Min-Chan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841669/ https://www.ncbi.nlm.nih.gov/pubmed/33552240 http://dx.doi.org/10.1177/1759720X20986732

Ejemplares similares

Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis
por: Park, Jun Won, et al.
Publicado: (2016)

Factors affecting drug survival of an alternative TNF inhibitor and secukinumab in patients with ankylosing spondylitis switching from the first TNF inhibitor
por: Kwon, Oh Chan, et al.
Publicado: (2021)

The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis
por: Lee, Suhwan, et al.
Publicado: (2019)

Frequency and characteristics of disease flares in ankylosing spondylitis
por: Cooksey, Roxanne, et al.
Publicado: (2010)

Dose Reduction of Tumor Necrosis Factor Inhibitor and its Effect on Medical Costs for Patients with Ankylosing Spondylitis
por: Koo, Bon San, et al.
Publicado: (2021)

Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
por: Kang, Ji-Hyoun, et al.
Publicado: (2014)

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis
por: Perpétuo, Inês P., et al.
Publicado: (2015)

Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set
por: Walsh, Jessica A., et al.
Publicado: (2018)

Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis
por: Lee, Jeong-Won, et al.
Publicado: (2015)

Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea
por: Jeong, Hyemin, et al.
Publicado: (2018)

Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis
por: Wang, Runsheng, et al.
Publicado: (2022)

Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis
por: Ma, Zeren, et al.
Publicado: (2017)

Palmoplantar pustulosis secondary to anti-tumor necrosis factor therapy in a patient with ankylosing spondylitis
por: Bae, Jung Min, et al.
Publicado: (2020)

Predictive factors of radiographic progression in ankylosing spondylitis
por: Kim, Hyungjin, et al.
Publicado: (2015)

Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry
por: Mease, Philip J., et al.
Publicado: (2018)

Gastrointestinal risk factors and patient‐reported outcomes of ankylosing spondylitis in Korea
por: Lee, Sang‐Hoon, et al.
Publicado: (2019)

Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry
por: Kim, Hyoun-Ah, et al.
Publicado: (2021)

The Epidemiology and Treatment of Ankylosing Spondylitis in Korea
por: Kwon, Seong-Ryul, et al.
Publicado: (2022)

Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
por: Tong, Qiang, et al.
Publicado: (2015)

Effect of tumor necrosis factor inhibitors on risk of cardiovascular disease in patients with axial spondyloarthritis
por: Kwon, Oh Chan, et al.
Publicado: (2022)

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
por: Lillegraven, Siri, et al.
Publicado: (2023)

Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors: Multinational Real-World Findings
por: Strand, Vibeke, et al.
Publicado: (2021)

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study
por: Deodhar, A., et al.
Publicado: (2020)

The impact of smoking status on radiographic progression in patients with ankylosing spondylitis on anti-tumor necrosis factor treatment
por: Nam, Bora, et al.
Publicado: (2022)

Impact of Tumor Necrosis Factor Inhibitor Versus Nonsteroidal Antiinflammatory Drug Treatment on Radiographic Progression in Early Ankylosing Spondylitis: Its Relationship to Inflammation Control During Treatment
por: Park, Jun Won, et al.
Publicado: (2018)

Correction: Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
por: Tong, Qiang, et al.
Publicado: (2015)

Clinical and genetic factors associated with radiographic damage in patients with ankylosing spondylitis
por: Nam, Bora, et al.
Publicado: (2023)

Disease flare of ankylosing spondylitis presenting as reactive arthritis with seropositivity: a case report
por: Manoj, EM, et al.
Publicado: (2012)

Cervical spine fracture in advanced ankylosing spondylitis
por: Lee, Jennifer, et al.
Publicado: (2014)

Liver enzyme elevation in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: a single-center historical cohort study
por: Choi, Su Jin, et al.
Publicado: (2020)

Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab
por: Lee, Sang‐Hoon, et al.
Publicado: (2020)

Serum Amyloid A as a Useful Indicator of Disease Activity in Patients with Ankylosing Spondylitis
por: Jung, Sang Youn, et al.
Publicado: (2007)

Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by (18)F-fluoride positron emission tomography
por: Bruijnen, Stefan T G, et al.
Publicado: (2018)

Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by (18)F-fluoride positron emission tomography
por: Bruijnen, Stefan T G, et al.
Publicado: (2018)

Autoantibodies against Protein Phosphatase Magnesium-Dependent 1A as a Biomarker for Predicting Radiographic Progression in Ankylosing Spondylitis Treated with Anti-Tumor Necrosis Factor Agents
por: Lee, Jung-Sun, et al.
Publicado: (2020)

Network Meta-Analysis and Cost Per Responder of Tumor Necrosis Factor-α and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis
por: Betts, Keith A., et al.
Publicado: (2016)

Incidence and predictors of morphometric vertebral fractures in patients with ankylosing spondylitis
por: Kang, Kwi Young, et al.
Publicado: (2014)

Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy
por: Suh, Young Sun, et al.
Publicado: (2014)

Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research
por: Kim, Hye Won, et al.
Publicado: (2016)

Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
por: Saad, Carla GS, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sd58j5ei7dod291o9hsu28sl0e